How can event-recording be accomplished in clinical trials ? Doctors already ask patients about their symptoms. Use of checklists increases the number of symptoms elicited, but may interfere with detection of the important ones.8 Patient questionnaires may be useful.9 The only developments needed are methods for recording all adverse events and for transmitting them to the co-ordinating centre. There they must be coded and analysed. This will require extra effort and expense, but need not prolong the trial period.
Because they include a few thousand patients at most, clinical trials of new drugs can provide information about only common adverse effects.10 This has led to pessimism about the value of trials in detecting toxicity, and attention has been focused on the undeniable importance of post-marketing surveillance. There are, however, several reasons why we should make the most of the trials that are done. Firstly, the commonest reactions are often the most important. Secondly, minor complaints may be a clue to more serious (although less common) toxicity, as would have been the case with practolol.' Thirdly, suspicions raised by clinical trials, even when firm conclusions are not possible, may lead to more effective monitoring after a drug is released."
It has recently been suggested that all doctors using new drugs should report adverse events to the Committee on Safety of Medicines, but it is doubtful if compliance could be ensured without some provision for automatically recording the use of the drugs, as Inman has proposed.'2 13 Event-recording in clinical trials is even more urgent and would be easier to implement. Its introduction could make the initial clinical trials much more effective.
Introduction
Management of breast carcinoma associated with pregnancy may be a severe test for any clinician. Widely differing views are held by surgeons, gynaecologists, and radiotherapists about its treatment and prognosis. In addition, non-clinical religious, psychological, and socioeconomic considerations will influence the choice of management.
The rarity of breast carcinoma during pregnancy means that no one institution can accumulate a wide experience, even over a long period. Only two large personal series have been published. Holleb and Farrow' reported on 283 patients from the Memorial Hospital for Cancer and Allied Diseases and Peters2 from the Ontario Cancer Institute reported on 126 patients in 1962, extending the series to 295 patients in 1968.3 Based on her extensive studies, Peters expressed strong views on the management of breast carcinoma associated with pregnancy. Clinicians have probably been most influenced by her views, which are widely quoted, and we have therefore compared and contrasted our findings with those of Peters. Concurrent pregnancy group-Patients where the breast carcinoma was diagnosed during pregnancy or up to one year after childbirth.
Subsequent pregnanicy group-Patients who became pregnant after completing treatment for primary breast carcinoma.
Eighty-eight patients were studied in the concurrent group and 40 patients in the subsequent pregnancy group. Three patients had two pregnancies each and therefore were included in both groups.
We have preferred to divide the phases of pregnancy into trimesters rather than into two halves as Peters has done, as we think that the former is more relevant to the practice of gynaecology and obstetrics in Britain.
Survival curves for various groups were calculated by the life-table method and compared by using the log-rank test4; this test was chosen because it compares the entire distributions of survival times rather than just the percentages of survivors at a fixed point in time-for example, five years.
Staging-All the patients had histological verification of carcinoma.
The pathological node state was also known in all the operable patients and was taken into account when staging the disease. Staging was according to the International Clinical Staging.
Incidenice-T T White' reviewed 1375 cases of breast carcinoma associated with pregnancy reported from 1866 to 1953 and added 38 cases to extend the series to 1413 patients.7 He calculated the frequency as three cases of breast carcinoma per 10 000 pregnancies, or 280, of all breast carcinomas. Peters3 placed the figure slightly higher at 3-8 % of all breast carcinomas. Almost 31 000 cases of breast carcinoma
